Comparative Pharmacology
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus VISIPAQUE 270.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLOGRAFIN MEGLUMINE versus VISIPAQUE 270.
CHOLOGRAFIN MEGLUMINE vs VISIPAQUE 270
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholografin meglumine is an iodinated contrast agent that opacifies the biliary tract. It is actively taken up by hepatocytes and excreted into the bile, allowing radiographic visualization of the bile ducts and gallbladder.
Iodinated radiocontrast agent; attenuates X-rays, providing vascular and tissue opacification.
Intravenous: 20 mL (10.3 g) of a 52% solution (meglumine salt) administered by slow IV injection over 3-5 minutes; repeated once after 10-15 minutes if visualization is inadequate, not to exceed 40 mL total.
Intraarterial or intravenous administration; dose depends on procedure, age, weight, cardiac output, and clinical condition. Typical adult dose: 50-150 mL of 270 mg I/mL (50-80 mL for coronary arteriography, 30-50 mL for left ventriculography; up to 250 mL total for multiple injections).
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal hepatic function, reflecting rapid biliary excretion; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function (creatinine clearance >60 mL/min). Prolonged in renal impairment, correlating with degree of kidney dysfunction.
Primarily hepatic excretion via bile into feces; renal excretion accounts for <1% of the dose in patients with normal hepatic function.
Renal excretion via glomerular filtration; >95% of administered dose eliminated unchanged in urine within 24 hours. Minimal biliary or fecal excretion (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent